JP2005505545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505545A5 JP2005505545A5 JP2003524516A JP2003524516A JP2005505545A5 JP 2005505545 A5 JP2005505545 A5 JP 2005505545A5 JP 2003524516 A JP2003524516 A JP 2003524516A JP 2003524516 A JP2003524516 A JP 2003524516A JP 2005505545 A5 JP2005505545 A5 JP 2005505545A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tyrphostin
- effective amount
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/945,192 US6433018B1 (en) | 2001-08-31 | 2001-08-31 | Method for reducing hypertrophy and ischemia |
| PCT/US2002/023444 WO2003020202A2 (en) | 2001-08-31 | 2002-07-23 | Method for reducing hypertension and heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010180146A Division JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505545A JP2005505545A (ja) | 2005-02-24 |
| JP2005505545A5 true JP2005505545A5 (enExample) | 2006-01-05 |
Family
ID=25482762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524516A Pending JP2005505545A (ja) | 2001-08-31 | 2002-07-23 | 高血圧及び心不全を減少させる方法 |
| JP2010180146A Pending JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010180146A Pending JP2010285455A (ja) | 2001-08-31 | 2010-08-11 | 高血圧及び心不全を減少させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6433018B1 (enExample) |
| EP (1) | EP1427401A4 (enExample) |
| JP (2) | JP2005505545A (enExample) |
| KR (1) | KR20040050894A (enExample) |
| AU (1) | AU2002313700B2 (enExample) |
| BR (1) | BR0212252A (enExample) |
| CA (1) | CA2458798C (enExample) |
| MX (1) | MXPA04001913A (enExample) |
| NZ (1) | NZ531693A (enExample) |
| WO (1) | WO2003020202A2 (enExample) |
| ZA (1) | ZA200402540B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20050038450A1 (en) * | 2003-06-03 | 2005-02-17 | Ping Hu | Methods and apparatus for minimally invasive transverse aortic banding |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| US20050130893A1 (en) * | 2003-09-30 | 2005-06-16 | Joan Smith-Sonneborn | Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure |
| EP2487156B1 (en) * | 2003-12-11 | 2014-07-16 | Board Of Regents The University Of Texas System | Compounds for treatment of cell proliferative diseases |
| TWI398261B (zh) * | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
| US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| US20100113481A1 (en) * | 2003-12-17 | 2010-05-06 | Alcon Research, Ltd. | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| US8691877B2 (en) * | 2004-10-15 | 2014-04-08 | Palo Alto Investors | Methods and compositions for treating a disease condition in a subject |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US10517876B2 (en) | 2005-11-16 | 2019-12-31 | Cti Biopharma Corp. | Oxygen linked pyrimidine derivatives |
| CN101360751B (zh) | 2005-11-16 | 2011-09-14 | S*Bio私人有限公司 | 氧连接的嘧啶衍生物 |
| AU2007205982A1 (en) * | 2006-01-13 | 2007-07-26 | President And Fellows Of Harvard College | Xenohormesis based compositions and methods |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| BRPI0708347A2 (pt) * | 2006-02-28 | 2011-05-24 | Cytopia Res Pty Ltd | inibição jak2 como um tratamento da hipertensão arterial pulmonar |
| WO2007115269A2 (en) | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| ES2521676T3 (es) | 2008-07-08 | 2014-11-13 | Board Of Regents, The University Of Texas System | Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS) |
| CN102282148B (zh) | 2008-12-11 | 2014-12-24 | Cti生物医药有限公司 | 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 |
| MX337849B (es) * | 2009-07-28 | 2016-03-09 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| JP5275966B2 (ja) * | 2009-12-21 | 2013-08-28 | パナソニック株式会社 | 繊維ボードの製造方法 |
| EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| CA2012634A1 (en) * | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| US6255296B1 (en) | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| US6358954B1 (en) * | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| DK1864677T3 (da) * | 2006-06-02 | 2008-04-28 | Teva Pharma | Stabil formulering omfattende et fugtsensitivt lægemiddel og fremstillingsmetoder deraf |
-
2001
- 2001-08-31 US US09/945,192 patent/US6433018B1/en not_active Expired - Lifetime
-
2002
- 2002-07-23 CA CA2458798A patent/CA2458798C/en not_active Expired - Fee Related
- 2002-07-23 MX MXPA04001913A patent/MXPA04001913A/es active IP Right Grant
- 2002-07-23 BR BR0212252-9A patent/BR0212252A/pt not_active IP Right Cessation
- 2002-07-23 EP EP02753409A patent/EP1427401A4/en not_active Withdrawn
- 2002-07-23 AU AU2002313700A patent/AU2002313700B2/en not_active Ceased
- 2002-07-23 NZ NZ531693A patent/NZ531693A/en not_active IP Right Cessation
- 2002-07-23 US US10/488,279 patent/US7235588B2/en not_active Expired - Lifetime
- 2002-07-23 WO PCT/US2002/023444 patent/WO2003020202A2/en not_active Ceased
- 2002-07-23 KR KR10-2004-7003111A patent/KR20040050894A/ko not_active Ceased
- 2002-07-23 JP JP2003524516A patent/JP2005505545A/ja active Pending
-
2004
- 2004-03-31 ZA ZA2004/02540A patent/ZA200402540B/en unknown
-
2010
- 2010-08-11 JP JP2010180146A patent/JP2010285455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9600071D0 (sv) | New oral formulation of two active ingredients I | |
| US6288118B1 (en) | Therapies for treating pulmonary diseases | |
| MY142403A (en) | Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient | |
| JP2007512371A5 (enExample) | ||
| Haas et al. | Critical care issues for the nephrologist: current diagnosis and management of hypertensive emergency | |
| JP2004538303A5 (enExample) | ||
| ECSP088422A (es) | Composiciones farmacéuticas sólidas que contienen pregabalina | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| JP2005532372A5 (enExample) | ||
| WO2003020202A3 (en) | Method for reducing hypertension and heart failure | |
| HRP20130424T4 (hr) | Postupci upotrebe sastava aminopiridina s odgođenim oslobađanjem | |
| WO2003039519A3 (es) | Forma de dosificación de liberación controlada dual | |
| DE60334924D1 (de) | Anoteilchengrösse | |
| CA2515293A1 (en) | Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage | |
| JP2003509401A5 (enExample) | ||
| WO2002089791A3 (de) | Behandlung der akne mit lipoxygenase inhibitoren | |
| JP2009517473A5 (enExample) | ||
| WO2003018061A1 (en) | Drugs containing chymase inhibitor and ace inhibitor as the active ingredients | |
| JP2006520801A5 (enExample) | ||
| AR054833A1 (es) | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina | |
| RU2014142066A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| ATE395050T1 (de) | Transdermales therapeutisches system für die verabreichung carboxylgruppenhaltiger, nichtsteroidaler antiphlogistika, sowie verfahren zu seiner herstellung | |
| EP3078386A3 (en) | Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor | |
| DK1677777T3 (da) | Pellets indeholdende venlafaxin-hydrochlorid | |
| WO2001082919A3 (en) | Methods of and compounds for inhibiting calpains |